Personalised vaccines will be tested on children with untreatable brain tumours as part of a world-first clinical trial ...

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

French drug company Sanofi announced it's discontinuing research and development for its next-generation mRNA flu vaccine. The post Drug company discontinues next-gen flu vaccine development as flu ...

The company, however, continues to work on a phase 1/2 study of its H5 mRNA flu vaccine for pandemic preparedness.

Sanofi halts plan mRNA seasonal flu vaccine, stopping phase 1 trial but continues work on mRNA pandemic flu vaccine with promising data.

The four-year trial of about 70 children with "dismal prognoses" in eight hospitals across Australia will test the safety and ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: boosting the immune system to better fight tumors during cancer treatment.

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...